Navigation Links
Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
Date:5/29/2012

BARCELONA, Spain and SAN DIEGO, May 29, 2012 /PRNewswire/ --- Hospital Universitari Vall d'Hebron Research Institute in Barcelona and Ocera Therapeutics, Inc. announced today preliminary data from an open label phase 2 study evaluating the overall effectiveness and safety of OCR-002 (ornithine phenylacetate) for the treatment of cirrhosis of the liver and upper GI bleeding. An interim analysis of the first cohort of patients demonstrated that OCR-002 is well tolerated and provided a rapid and durable ammonia reduction after 36 hours of treatment. The data were presented at the 15th International Symposium for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) in Grenaa, Denmark.

OCR-002 is a novel injectable agent that removes toxic, circulating ammonia from the blood. In patients with severe liver impairment, ammonia and other toxic substances that are normally removed by the liver accumulate in the blood and impair the function of brain cells. By removing circulating ammonia, OCR-002 may treat or prevent hepatic encephalopathy (HE), a neuropsychiatric complication of acute liver failure associated with increased levels of circulating ammonia. Signs of HE include impaired cognition, uncontrolled movements and decreased levels of consciousness leading to coma and even death.

"These early data demonstrate that OCR-002 is well tolerated, rapidly normalizes hyperammonemia and has the potential to prevent the development of hepatic encephalopathy," said Dr. Juan Cordoba of Hospital Universitari Vall d'Hebron and the lead investigator of the study. "Cirrhosis patients that present with acute upper gastrointestinal bleeding have a 30% chance of developing hepatic encephalopathy and require intensive care. A medicine that can quickly remove the toxic ammonia may help prevent or reverse this life-threatening condition, minimize the need for intensive care and shorten hospitalization."

The data presented today from the study of Upper GI bleed in
'/>"/>

SOURCE Ocera Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
2. Cardinal Health Statement in Response to Preliminary Injunction Hearing February 29, 2012
3. Vermillion to Report Preliminary Results for Fourth Quarter and Fiscal Year 2011 on February 23, 2012
4. Watson Confirms Court Stays Preliminary Injunction
5. Watson Announces Preliminary 2011 Non-GAAP Earnings of $4.75-$4.77
6. Hill-Rom Announces Preliminary Fiscal First Quarter Financial Results; Updates 2012 Financial Outlook
7. Volcano Corporation Announces Preliminary Fourth Quarter 2011 Revenues
8. CareFusion Announces Preliminary Second Quarter Results
9. Sanofi Announces Court Ruling Granting Preliminary Injunction Against Synvisc-One® Competitor Product
10. InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights
11. PDL BioPharma Announces Expiration and Preliminary Results of its Exchange Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015  Seeger Weiss LLP is reporting that on ... warning letter to C.R. Bard, the manufacturer of Inferior ... to correct violations the agency found at two of Bard,s ... the FDA cited them during Inspectional Observations that occurred on ... Tempe, AZ , location and on October 6, ...
(Date:7/31/2015)... 31, 2015  Boston Children,s Hospital physicians report ... printing of their anatomy before undergoing high-risk brain ... (abnormalities in the brain,s blood vessels) that posed ... in the Journal of Neurosurgery: Pediatrics , ... and synthetic resins to create custom, high-fidelity models ...
(Date:7/31/2015)... PORTLAND, Ore., July 31, 2015  Semler Scientific, Inc. ... and testing services to healthcare insurers and physician groups, ... June 30, 2015. "In the second ... over year revenue growth of 54%, quarter over quarter ... of the installed base of FloChec® units of 18%," ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 33D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
... A number of costs associated with nonprescription drug ... and a half years. Certain material costs for plastic ... during this time, increasing packaging expenses. Advertising and marketing ... the majority of marketers reduced advertising costs in 2009, ...
... ERT (Nasdaq: ERES ) announced today ... 2010 on Thursday, November 4, 2010, after the market closes. ... at 5:00 PM EDT that day. For ... within the United States or 1-412-858-4600 when calling internationally. There ...
Cached Medicine Technology:Nonprescription Drugs Cost Structures Fluctuate with Increased Cost of Goods, According to Kline 2Nonprescription Drugs Cost Structures Fluctuate with Increased Cost of Goods, According to Kline 3ERT to Announce Third Quarter 2010 Results on November 4, 2010 2
(Date:8/3/2015)... Hollywood, FL (PRWEB) , ... ... ... internet’s most-visited bodybuilding and fitness site and the largest online retailer of ... Supplement Awards. BPI Sports is up for 11 awards in the following ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... of its industry-defining contract lifecycle management solution, as well as announced the date ... increase the speed and ease of contract management tasks as well as enhancements ...
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing ... the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le ... of the Company’s presentation may be accessed via the investor relations section of the ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug ... Kybella is similar to deoxycholic acid, which occurs naturally in the body and helps ... to treat this area of the body. These are invasive procedures and very expensive ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... predicted to decline by 39 percent, according to market research compiled for the ... data from the U.S. Department of Labor, Bureau of Labor Statistics. As the ...
Breaking Medicine News(10 mins):Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3
... Dec. 17 HealthSouth,Corporation (NYSE: HLS ) today ... EST on Tuesday, Feb. 24, 2009, to discuss its results ... The conference call may ... 76626362. International callers should dial (973) 582-2847 and,give the same ...
... ATLANTA, Dec. 17, 2008, The AMERIGROUP Foundation announced ... Outreach worker at West End Medical Centers, by designating ... Ms. Roper has contributed significantly to the ... years of extensive neighborhood involvement. For the past ...
... those with pulmonary clots saw benefit, , , WEDNESDAY, Dec. ... the clot-dissolving drug tenecteplase (TKNase) to people with sudden ... a form of tissue plasminogen activator (tPA), didn,t work ... up on the idea. , "In specific situations, those ...
... 17 Human Pheromone,Sciences, Inc. (OTC Bulletin Board: EROX) ... Comprehensive Patent Application with the U.S. Patent and,Trademark Office ... with its origin in sea coral, which has significant ... positive social relationships,personal well-being and social attraction. , ...
... request of the presidential transition team, ideas on advancing ... today by the American College of Physicians (ACP). ... student members. It is the nation,s largest medical ... membership organization. , "ACP believes that it is essential ...
... leader in the planning and development of sustainable, social and ... Dr. Theresa Ramsey,s Center For Natural Healing to create OTP2 ... the focus of the collaboration - to provide consulting services ... , , OTP2 brings together ...
Cached Medicine News:Health News:HealthSouth Announces Date of 2008 Fourth Quarter and Year-End Earnings Conference Call 2Health News:Fredericka Roper of Atlanta Honored as 'Healthy Hero' By the AMERIGROUP Foundation 2Health News:Clot Dissolver Doesn't Boost Survival in Cardiac Arrest Patients 2Health News:Clot Dissolver Doesn't Boost Survival in Cardiac Arrest Patients 3Health News:HPS Files Patent for Mood-Enhancing Compound Naturally Found in Sea Coral 2Health News:Internists ask President-elect Obama to include aid for primary care in stimulus proposal 2Health News:Internists ask President-elect Obama to include aid for primary care in stimulus proposal 3Health News:Pyramid Developers and Dr. Ramsey's Center for Natural Healing Announce Formation of Community Health and Wellness Planning Collaborative. 2Health News:Pyramid Developers and Dr. Ramsey's Center for Natural Healing Announce Formation of Community Health and Wellness Planning Collaborative. 3Health News:Pyramid Developers and Dr. Ramsey's Center for Natural Healing Announce Formation of Community Health and Wellness Planning Collaborative. 4
... might just be the world's most versatile ... support, post-op/rehab support, or both, Flex is ... Accutrac™ ROM hinges control flexion and extension ... durability while being heat-moldable to accommodate changes ...
... The Drytex Adjustable Patella Donut is ... unique nylon core and polyester Lycra ... A trimable full-circumference donut provides for ... have neoprene based allergies or irritations. ...
... The cool version of the TROM ... range-of-motion and locking capabilities as the full ... warmer climates. The ease of use and ... a variety of protocols following major ligament ...
Provides range-of-motion control for both flexion and extension along with a drop lock feature...
Medicine Products: